| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
TLR9
FAM-labeled ODN 1826 sodium targets Toll-like receptor 9 (TLR9), which is expressed in endosomes of immune cells such as plasmacytoid dendritic cells and B cells. The CpG motif (unmethylated cytosine-guanine dinucleotides) is recognized by TLR9, activating MyD88-dependent signaling and inducing pro-inflammatory cytokines. The FAM label allows visualization of uptake and trafficking. |
|---|---|
| ln Vitro |
In cell-based assays, FAM-labeled ODN 1826 sodium is used to track the cellular uptake and endosomal localization of CpG ODNs. Immune cells are incubated with the labeled ODN (1-10 microM) for 1-24 hours. Cells are then fixed and imaged by confocal microscopy to observe endosomal puncta. Flow cytometry quantifies the percentage of cells that have taken up the ODN and the fluorescence intensity.
|
| ln Vivo |
In vitro, FAM-labeled ODN 1826 sodium activates TLR9 signaling. Cells are treated with the ODN (1-10 microM), and cytokine production (e.g., IL-6, TNF-alpha, IFN-alpha) is measured by ELISA. It also induces NF-kappaB activation, which can be measured by reporter gene assays. It has been shown to ameliorate cardiac dysfunction after trauma-hemorrhage.
|
| Enzyme Assay |
For confocal microscopy, immune cells (e.g., RAW264.7 macrophages or splenocytes) are seeded in chamber slides and treated with FAM-labeled ODN 1826 sodium (1-10 microM) for 1-24 hours. Cells are washed, fixed with 4% paraformaldehyde, permeabilized (if intracellular staining is needed), and stained with DAPI for nuclei. Images are acquired using a confocal microscope (ex 488 nm, em 520 nm).
|
| Cell Assay |
For flow cytometry, cells are incubated with FAM-labeled ODN 1826 sodium (1-10 microM) in 12- or 24-well plates for 1-24 hours. Cells are washed, trypsinized (if adherent), and resuspended in FACS buffer. Fluorescence intensity is measured using a flow cytometer (488 nm laser, 530/30 nm filter). Data is analyzed with FlowJo or similar software to determine uptake percentage.
|
| Animal Protocol |
In vivo, FAM-labeled ODN 1826 sodium can be used to track ODN biodistribution. Mice are injected intravenously or intraperitoneally with the labeled ODN (1-5 mg/kg). After 1-24 hours, mice are euthanized, and tissues (spleen, lymph nodes, liver) are collected. Tissue sections are prepared and imaged by confocal microscopy for FAM fluorescence to assess TLR9-expressing cell uptake.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for FAM-labeled ODN 1826 sodium is limited. ODNs are generally rapidly cleared from circulation by nucleases and renal excretion. The FAM label may be stable for a few hours. For research use, store as a lyophilized powder at -20degC, protected from light. Reconstitute in sterile, nuclease-free water or PBS.
|
| Toxicity/Toxicokinetics |
Toxicity data for FAM-labeled ODN 1826 sodium is not available. ODNs have low toxicity at research doses. The FAM label may be a mild irritant. Standard laboratory precautions should be followed. Not for human therapeutic use.
|
| References |
|
| Additional Infomation |
FAM-labeled ODN 1826 sodium is a research reagent, not an approved drug. It is used to study TLR9 activation, CpG ODN uptake, and endosomal trafficking. It is a class B CpG ODN and is used in immunology and vaccine research. It is for laboratory use only and not for human consumption. Purity >95% by HPLC.
|
| Appearance |
Light yellow to yellow solid powder
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
